A Non-Interventional Study Evaluating The Effects Of Aromatase Inhibitor Treatment After 2-3 Years Tamoxifen - As Adjuvant Endocrine Therapy - On Quality Of Life And Safety In Endocrine Responsive Early Stage Postmenopausal Breast Cancer Patients

Pfizer1 site in 1 country344 target enrollmentJune 2008

ConditionsBreast Neoplasms

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Breast Neoplasms
Sponsor: Pfizer
Enrollment: 344
Locations: 1
Primary Endpoint: To evaluate the quality of life of patients with early stage postmenopausal breast cancer using aromatase inhibitor following 2-3 years of tamoxifen treatment (switch)
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.

Detailed Description

Group of patients using the same aromatase inhibitor

Registry

clinicaltrials.gov

Start Date

June 2008

End Date

December 2011

Last Updated

14 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Pfizer

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with endocrine responsive early stage postmenopausal breast cancer. Patients who received tamoxifen for 2-3 years as adjuvant endocrine therapy. Patients who were approved to switch to aromatase inhibitor treatment during the patient recruitment period.
•Patients who were informed about the study and accepted to participate.

Exclusion Criteria

•Patients having a psychological disorder which will prevent their understanding of questionnaires used for evaluation of quality of life and / or patients who are illiterate.

Outcomes

Primary Outcomes

To evaluate the quality of life of patients with early stage postmenopausal breast cancer using aromatase inhibitor following 2-3 years of tamoxifen treatment (switch)

Time Frame: 2 years

Secondary Outcomes

To evaluate patients with early stage postmenopausal breast cancer using aromatase inhibitor following 2-3 years of tamoxifen treatment (switch) in terms of side effects(2 years)